Navigation Links
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
Date:9/25/2008

Presentations Include Proof-of-Concept Animal Data on Previously Disclosed Fusion Protein TT30 and New Molecules TT32 and mAb171

CAMBRIDGE, Mass., Sept. 25 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that data from in vivo disease models on several of the company's pipeline candidates will be presented next week at the XXII International Complement Workshop in Basel, Switzerland.

The data, which will be presented in eight oral and poster presentations, are the results of research conducted by the laboratories of Michael Holers, M.D., chief scientific officer of Taligen, and the company's academic collaborators in the complement research community. Five studies testing the company's fusion protein TT30 and two new compounds, a fusion protein TT32 and a monoclonal antibody mAb171, in animal models are highlighted below. These data further support Taligen's approach that targeting the alternative complement pathway can impact complement-mediated inflammatory disease processes.

Poster Presentations:

TT30

Targeted inhibition of the alternative pathway by CR2-fH fusion protein ameliorates progression of renal disease in MRL/lpr mice

Hideharu Sekine*, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 174

Alternative complement pathway signaling in a mouse model of choroidal neovascularisation

Barbel Rohrer*, Qin Long, Brooks Wilson, Beth Coughlin, Yuxiang Huang, Fei Qiao, Peter Tang, Kannan Kunchithapautham, Gary Gilkeson, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 202

TT30 and TT32

Targeted complement-inhibitory proteins CR2-Crry and CR2-fH ameliorate allergen-induced airway hyperresponsiveness and inflammation

Joshua Thurman*, Katsuyuki Takeda, Stephen Tomlinson, Erwin Gelfand, V. Michael Holers

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 171

The role
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
2. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
5. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
8. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
9. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
10. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
11. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...ACH, Fla., Nov. 7 Most patients wi...toms that signal an oncoming HAE attack giving the...d decrease the morbidity associated with that atta...t the 2009 American College of Allergy, Asthma &am...ition of symptoms such as fatigue and nausea, whic...
(Date:11/6/2009)...N.C., Nov. 6 Oxygen Biot... announced that a previously approved reverse spli...t of trading on Monday, Nov. 9, 2009 on a 1-for-15.... shares will trade under the new symbol OXBT. The...0 9, when the split becomes effective. ,, "This...
(Date:11/6/2009)..., FORT WASHINGTON, Pa., Nov. 6 In ...ation (FDA), McNeil Consumer Healthcare, Division ...all of a limited number of product lots of TYLENOL...th the distinctive red EZ-OPEN CAP. McNeil is init...istic smell or taste associated with these lots th...
Breaking Medicine Technology:Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Craneware Announces Fiscal Year End Results 56424 1Craneware Announces Fiscal Year End Results 56424 2Craneware Announces Fiscal Year End Results 56424 3Invision Sally Jobe Names Breast Network Medical Director 56421 1Invision Sally Jobe Names Breast Network Medical Director 56421 2Cancer Drug May Fight Alzheimers 56418 1
...for Sept. 29, LA JOLLA, Calif., June 30 TorreyPi...nced that data presented at the 50th Annual,Scient...ed that, in,addition to meeting the primary endpoi...ny,s lead AMPA/kainate-type glutamate receptor ant...portant secondary endpoints in a,306-patient Phase...
...s Corporation (Nasdaq: UTHR ) and its wholly-owne...bmission of a New Drug Application,(NDA) to the U....g approval,of an inhaled formulation of treprostin...hypertension (PAH), a chronic, life-threatening di...g which the FDA will examine the,application for c...
Other Medicine Technology:Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration 2New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration 3New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration 4
(Date:11/9/2009)...ith new cells regained sexual function, study says... -- Researchers were able to restore sexual functi...penile tissue in the lab and implanting it, a new ...a ways off, researchers say the technique could on... in men. , "We were able to show the tissue was...
(Date:11/9/2009)...na, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat ...d today that Novartis, a US$41 billion internation...n HTDS, H1N1 Vaccine partner, Zhejiang Tianyuan Bi...vartis of Switzerland will begin a five-year, $1 b... will dramatically increase its investment in its ...
(Date:11/9/2009)... Tomorrow may be too late when it comes to p...ding to TOPS Club, Inc. (Take Off Pounds Sensibly)... , (Vocus) November 9, 200...venting or improving a diabetes condition, accordi...the nonprofit weight-loss support organization., ,...
(Date:11/9/2009)... New study highlights positive influence of ... Rosemont, IL (Vocus) November 9, 2009...th decreases. Recent research has highlighted the ...help prevent these issues. However, a new study pu...Health: A Multidisciplinary Approach reveals that...
(Date:11/9/2009)... Calif., Nov. 9 Actress Mariska Ha... philosophy on Saturday to raise awareness abou...throughout California by building healing and well...ts were created to give one to each of the estimat...Angeles County,s domestic violence shelters. ,,...
Breaking Medicine News(10 mins):Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3
... six months old is not advisable as it may lead to...uld rather breastfeed them exclusively, scientists...oided for the first six months, and certain items ...ACAAI), reported online edition of health magazine...
...scarriage, for a couple, appears to rise along wit... mother// according to a recent report by research...They conducted their study on nearly 14,000 women ...icipants who delivered a baby. The researchers fou...
...ia have suggested that cross-immunity created in r...in protect against infection // by related seroty...engue epidemics. This finding would help understa...he dominant serotype," said lead author Helen Wear...
... disease caused by filarial worm Onchocerca volvul...s craw craw is an endemic disease in Bioko Island,... black flies causes weakening in affected individu...he environmental conditions and altitude of Bioko ...
...iversity of Florida, Gainesville, mice based exper...enes to treat hereditary diseases of the heart.// ... in mice affected with muscular dystrophy that dam...soon as early next year for patients with Pompe di...
... of north India, encephalitis has once again struc...e virus has already claimed the lives of 36 childr...ies claim the currently spreading virus was not th... any of the 223 cases that have been reported sinc...
Other Medicine News:Health News:Risk of Miscarriage Rises with Father’s Ag 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3Health News:River Blindness Incidence Reduced With Effective Treatment 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4Health News:36 Children Die of Encephalitis in Uttar Pradesh 2
MYO-VAD™ Cardiac Assist Device
LOGIQ Book XP
Rio™ Aspiration Catheter
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
Medicine Products: